C Debruyne
Overview
Explore the profile of C Debruyne including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
239
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Efficace F, Bottomley A, Smit E, Lianes P, LeGrand C, Debruyne C, et al.
Ann Oncol
. 2006 Sep;
17(11):1698-704.
PMID: 16968876
Background: The aim of this prognostic factor analysis was to investigate if a patient's self-reported health-related quality of life (HRQOL) provided independent prognostic information for survival in non-small cell lung...
2.
Debruyne C
Tijdschr Psychiatr
. 2006 Sep;
48(2):107-17.
PMID: 16958194
Background: The therapeutic use of melatonin in children is based on research into the properties of the product and on experience gained from its use in specific populations. Our knowledge...
3.
OBrien M, Splinter T, Smit E, Biesma B, Krzakowski M, Tjan-Heijnen V, et al.
Eur J Cancer
. 2003 Jun;
39(10):1416-22.
PMID: 12826045
The aim of this study was to document the activity and toxicity of paclitaxel (Taxol)/carboplatin when used as induction chemotherapy in patients with stage IIIA N2 non-small cell lung cancer...
4.
Dziadziuszko R, Ardizzoni A, Postmus P, Smit E, Price A, Debruyne C, et al.
Eur J Cancer
. 2003 May;
39(9):1271-6.
PMID: 12763216
This study was performed to evaluate the activity of single-agent temozolomide in two groups of chemotherapy-naïve non-small cell lung cancer (NSCLC) patients, with (12 patients) and without (13 patients) brain...
5.
Baas P, Ardizzoni A, Grossi F, Nackaerts K, Numico G, Marck E, et al.
Eur J Cancer
. 2003 Feb;
39(3):353-7.
PMID: 12565988
We investigated the activity and toxicity of raltitrexed (Tomudex) as a single agent treatment in patients with Malignant Pleural Mesothelioma (MPM) in a multicentre phase II European Organization for Research...
6.
Tjan-Heijnen V, Caleo S, Postmus P, Ardizzoni A, Burghouts J, Buccholz E, et al.
Ann Oncol
. 2003 Feb;
14(2):248-57.
PMID: 12562652
Background: To determine whether the cost of prophylactic antibiotics during chemotherapy is offset by cost savings due to a decreased incidence of febrile leukopenia (FL). Patients And Methods: Small-cell lung...
7.
Van Meerbeeck J, Baas P, Debruyne C, Smit E, van Klaveren R, Galdermans D, et al.
Eur J Cancer
. 2002 Apr;
38(6):779-83.
PMID: 11937311
The aim of this study was to investigate the anti-tumour activity of temozolomide in patients with malignant pleural mesothelioma. 27 chemotherapy-naïve patients with histologically-proven malignant mesothelioma were treated with temozolomide...
8.
Debruyne C, Giaccone G
Eur J Cancer
. 2002 Feb;
38 Suppl 4:S100-6.
PMID: 11858974
The EORTC Lung Cancer Group (LCG) is a multidisciplinary international group of experts performing clinical research in lung cancer since 1962. Originally, the group consisted mainly out of French and...
9.
Bernier J, Vermorken J, Debruyne C, Andry G, Licitra L, Grandi C, et al.
Eur J Cancer
. 2002 Feb;
38 Suppl 4:S75-81.
PMID: 11858970
The purpose of this article is to review the most significant results of the clinical studies conducted in the past two decades by the EORTC Head and Neck Cancer Group...
10.
Tjan-Heijnen V, Postmus P, Ardizzoni A, Manegold C, Burghouts J, Van Meerbeeck J, et al.
Ann Oncol
. 2002 Jan;
12(10):1359-68.
PMID: 11762805
Background: CDE (cyclophosphamide, doxorubicin, etoposide) is one of the standard chemotherapy regimens in the treatment of small-cell lung cancer (SCLC), with myelosuppression as dose-limiting toxicity. In this trial the impact...